The benefits from new vaccines may not be distributed evenly across age or ethnic groups, between sexes, or among other subsets of the population. The method designed by the committee can provide useful information on the distribution of benefits that could accrue from different courses of action, but the committee recommends that decisions regarding selection of an equitable course of action should be addressed in a broader political/public policy forum.
The public perception of adverse reactions to the current pertussis vaccine is damaging generally to efforts to promote immunization, and thus development of an improved pertussis vaccine merits special consideration.
In implementing the program of accelerated vaccine development, NIAID periodically should review activity in the private sector to identify projects on which public-private collaboration might expedite development; and to overcome industry-scientific disincentives to development of high priority vaccines.
In the ultimate selection of a portfolio of candidates for accelerated vaccine development, information obtained from the analysis described in Chapters 3, 7, and 9 must be integrated with the non-quantifiable considerations discussed above.
Fulginiti, V.A. 1984. Editorial. Pertussis disease, vaccine and controversy. JAMA 251(2):251.
Gunby, P. 1983. Genital herpes research: Many aim to tame the maverick virus. JAMA 250(18):2417–2419, 2423–2424, 2427.
Linnemann, C.C., Jr., F.C.Robbins, and C.R.Manclark. 1983. Public and Scientific Affairs Board (American Society for Microbiology) statement on pertussis vaccine. Am. Soc. Microbiol. News 49:580–581.
Wilson, T. 1984. Engineering tomorrow’s vaccines. Bio/Technology 2:28–39.